JP2018535670A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535670A5
JP2018535670A5 JP2018521983A JP2018521983A JP2018535670A5 JP 2018535670 A5 JP2018535670 A5 JP 2018535670A5 JP 2018521983 A JP2018521983 A JP 2018521983A JP 2018521983 A JP2018521983 A JP 2018521983A JP 2018535670 A5 JP2018535670 A5 JP 2018535670A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
hvr
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018521983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535670A (ja
JP6949016B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/075884 external-priority patent/WO2017072210A1/en
Publication of JP2018535670A publication Critical patent/JP2018535670A/ja
Publication of JP2018535670A5 publication Critical patent/JP2018535670A5/ja
Priority to JP2021152748A priority Critical patent/JP7305719B2/ja
Application granted granted Critical
Publication of JP6949016B2 publication Critical patent/JP6949016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018521983A 2015-10-29 2016-10-27 抗バリアントFc領域抗体および使用法 Active JP6949016B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021152748A JP7305719B2 (ja) 2015-10-29 2021-09-21 抗バリアントFc領域抗体および使用法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192195 2015-10-29
EP15192195.4 2015-10-29
PCT/EP2016/075884 WO2017072210A1 (en) 2015-10-29 2016-10-27 Anti-variant fc-region antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021152748A Division JP7305719B2 (ja) 2015-10-29 2021-09-21 抗バリアントFc領域抗体および使用法

Publications (3)

Publication Number Publication Date
JP2018535670A JP2018535670A (ja) 2018-12-06
JP2018535670A5 true JP2018535670A5 (enExample) 2019-11-28
JP6949016B2 JP6949016B2 (ja) 2021-10-13

Family

ID=54361020

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521983A Active JP6949016B2 (ja) 2015-10-29 2016-10-27 抗バリアントFc領域抗体および使用法
JP2021152748A Active JP7305719B2 (ja) 2015-10-29 2021-09-21 抗バリアントFc領域抗体および使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021152748A Active JP7305719B2 (ja) 2015-10-29 2021-09-21 抗バリアントFc領域抗体および使用法

Country Status (10)

Country Link
US (2) US10899845B2 (enExample)
EP (2) EP3368568B1 (enExample)
JP (2) JP6949016B2 (enExample)
KR (2) KR102731208B1 (enExample)
CN (3) CN114891102A (enExample)
AU (1) AU2016344665C1 (enExample)
CA (2) CA3293011A1 (enExample)
IL (2) IL295756A (enExample)
MX (2) MX2018005036A (enExample)
WO (1) WO2017072210A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9731113B2 (en) 2014-12-30 2017-08-15 The Spectranetics Corporation Collapsing coil coupling for lead extension and extraction
US9884184B2 (en) 2014-12-30 2018-02-06 The Spectranetics Corporation Wire hook coupling for lead extension and extraction
IL269531B2 (en) 2017-03-27 2024-10-01 Hoffmann La Roche Improved antigen binding receptors
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
JP7425725B2 (ja) * 2017-12-07 2024-01-31 中外製薬株式会社 試料中のポリペプチドの検出または捕捉において使用するための抗体、組成物、および試料中のポリペプチドの検出または捕捉のための方法
EP3729080B1 (en) 2017-12-21 2023-04-19 F. Hoffmann-La Roche AG Universal reporter cell assay for specificity test of novel antigen binding moieties
AR115730A1 (es) * 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
CN118271445A (zh) 2018-12-21 2024-07-02 豪夫迈·罗氏有限公司 与cd3结合的抗体
EP3956365A4 (en) * 2019-04-19 2023-07-05 Chugai Seiyaku Kabushiki Kaisha ANTIBODIES AND COMPOSITIONS FOR USE IN DETECTING OR CAPTURE OF A POLYPEPTIDE IN A SAMPLE AND METHODS OF DETECTING OR CAPTURE OF A POLYPEPTIDE IN A SAMPLE
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
MX2022015887A (es) 2020-06-19 2023-01-24 Hoffmann La Roche Anticuerpos que se unen a cd3 y folr1.
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
MX2022015203A (es) * 2020-06-19 2023-01-05 Hoffmann La Roche Moleculas de union al dominio fc de activacion inmunitaria.
CA3177239A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific antibodies
AR122658A1 (es) 2020-06-19 2022-09-28 Hoffmann La Roche Anticuerpos que se unen a cd3
CR20230263A (es) 2020-12-17 2023-08-21 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos
JP2024534067A (ja) 2021-08-19 2024-09-18 エフ. ホフマン-ラ ロシュ アーゲー 多価抗バリアントfc領域抗体および使用方法
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
CN118924893A (zh) * 2023-05-10 2024-11-12 信达细胞制药(苏州)有限公司 Bcmap329g抗体及car-t细胞在治疗多发性骨髓瘤中的应用
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1989012231A1 (en) * 1988-06-08 1989-12-14 Cambridge Bioscience Corporation Anti-fc assay for detection of antibodies
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
ZA898290B (en) 1988-11-03 1991-06-26 Igen Inc Electrochemiluminescent assays
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
SG176455A1 (en) 2003-10-09 2011-12-29 Ambrx Inc Polymer derivatives
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CN105624118B (zh) 2009-10-19 2019-08-13 弗·哈夫曼-拉罗切有限公司 非交叉反应性抗IgG抗体
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
JP2013528357A (ja) * 2010-03-29 2013-07-11 ザイムワークス,インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
BR112015000665A2 (pt) * 2012-07-13 2017-06-27 Hoffmann La Roche método para a determinação da quantidade de um anticorpo
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
EP2992010B1 (en) * 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
BR112016016411A2 (pt) * 2014-01-15 2017-10-03 Hoffmann La Roche VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS

Similar Documents

Publication Publication Date Title
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
CN110431231B (zh) 抗-cd3抗体和包含所述抗体的分子
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
JP2010502183A5 (enExample)
JP2022548066A5 (enExample)
CN110066336B (zh) 抗cd47单克隆抗体、片段及其医药用途
HRP20221141T1 (hr) Anti-lag3 protutijela
TW201915026A (zh) Tigit抗體、其抗原結合片段及醫藥用途
JP2019116474A5 (enExample)
JP2017149720A5 (enExample)
AU2016238246A1 (en) Multi-valent hepatitis B virus antigen binding molecules and uses thereof
RU2012112829A (ru) Анти-gitr-антитела
JP2015506912A5 (enExample)
HRP20180352T1 (hr) Protutijela anti-fcrh5
FI3310812T3 (fi) Anti-her2-vasta-aineita ja käyttömenetelmiä
JP2020524510A5 (enExample)
JP2016516400A5 (enExample)
JP2015508056A5 (enExample)
JP2013535191A5 (enExample)
JP2021500916A5 (enExample)
RU2016118573A (ru) Анти-ly6e антитела и способы применения
JP2013539962A5 (enExample)
RU2013105487A (ru) Антитела против нейропилина и способы их применения
JP2024535793A (ja) Pd-1に特異的に結合するタンパク質及びその医薬的使用
CN109721656B (zh) 靶向rankl的治疗性抗体